Literature DB >> 17504219

Expression and function of cytochrome p450 in brain drug metabolism.

R P Meyer1, M Gehlhaus, R Knoth, B Volk.   

Abstract

Cytochrome P450 (CYP, P450) is the collective term for a superfamily of heme-containing membrane proteins responsible for the metabolism of approximately 70 - 80 % of clinically used drugs. Besides the liver and other peripheral organs, P450 isoforms are expressed in glial cells and neurons of the brain. To enlighten their function and significance is a topic of high interest, as most of the neuroactive drugs used in therapy today are not only substrates, but also inducers of brain P450s with far reaching consequences. First of all, brain P450s are regulated differentially from those in liver. The availability of the prosthetic heme group appears to be essential for correct membrane insertion and enzymatic functionality of brain P450s. Furthermore, although not contributing to body's overall drug metabolism, brain P450s fulfil particular functions within specific cell types of the brain. In astrocytes of brain's border lines P450 isoforms are expressed at very high level. They form a metabolic barrier regulating drugs' influx, modulate blood-flow regulation, and act as signalling enzymes in inflammation. In neurons, however, P450s apparently have different function. In specified brain regions such as hypothalamus, hippocampus and striatum they provide signalling molecules like steroids and fatty acids necessary for neuronal outgrowth and maintenance. Induction of these P450s by neuroactive drugs can alter steroid hormone signalling directly in drug target cells, which may cause clinically relevant side effects like reproductive disorders and sexual or mental dysfunction. The understanding of brain P450 function appears to be of major interest in long-term drug mediated therapy of neurological diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17504219     DOI: 10.2174/138920007780655478

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  55 in total

1.  Neurobehavioral abnormalities in a brain-specific NADPH-cytochrome P450 reductase knockout mouse model.

Authors:  C Fang; V J Bolivar; J Gu; W Yang; S O Zeitlin; X Ding
Journal:  Neuroscience       Date:  2012-05-22       Impact factor: 3.590

2.  Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2008-07-30       Impact factor: 7.853

Review 3.  Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

Authors:  William E Fantegrossi; Jeffery H Moran; Anna Radominska-Pandya; Paul L Prather
Journal:  Life Sci       Date:  2013-09-29       Impact factor: 5.037

4.  Astrocytes: Everything but the glue.

Authors:  Oscar Gonzalez-Perez; Veronica Lopez-Virgen; Alfredo Quiñones-Hinojosa
Journal:  Neuroimmunol Neuroinflamm       Date:  2015 Apr-Jun

5.  Modulation of intercellular junctions by cyclic-ADT peptides as a method to reversibly increase blood-brain barrier permeability.

Authors:  Marlyn D Laksitorini; Paul K Kiptoo; Ngoc H On; James A Thliveris; Donald W Miller; Teruna J Siahaan
Journal:  J Pharm Sci       Date:  2015-01-12       Impact factor: 3.534

6.  Δ9-Tetrahydrocannabinol changes the brain lipidome and transcriptome differentially in the adolescent and the adult.

Authors:  Emma Leishman; Michelle Murphy; Ken Mackie; Heather B Bradshaw
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-02-08       Impact factor: 4.698

7.  Blood-brain barrier damage and brain penetration of antiepileptic drugs: role of serum proteins and brain edema.

Authors:  Nicola Marchi; Giulia Betto; Vincent Fazio; Quinyuan Fan; Chaitali Ghosh; Andre Machado; Damir Janigro
Journal:  Epilepsia       Date:  2009-01-21       Impact factor: 5.864

Review 8.  Nanotechnology: toxicologic pathology.

Authors:  Ann F Hubbs; Linda M Sargent; Dale W Porter; Tina M Sager; Bean T Chen; David G Frazer; Vincent Castranova; Krishnan Sriram; Timothy R Nurkiewicz; Steven H Reynolds; Lori A Battelli; Diane Schwegler-Berry; Walter McKinney; Kara L Fluharty; Robert R Mercer
Journal:  Toxicol Pathol       Date:  2013-02-06       Impact factor: 1.902

9.  Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.

Authors:  Krishna C Chimalakonda; Kathryn A Seely; Stacie M Bratton; Lisa K Brents; Cindy L Moran; Gregory W Endres; Laura P James; Paul F Hollenberg; Paul L Prather; Anna Radominska-Pandya; Jeffery H Moran
Journal:  Drug Metab Dispos       Date:  2012-08-17       Impact factor: 3.922

Review 10.  Imbalance between thyroid hormones and the dopaminergic system might be central to the pathophysiology of restless legs syndrome: a hypothesis.

Authors:  Jose Carlos Pereira; Marcia Pradella-Hallinan; Hugo de Lins Pessoa
Journal:  Clinics (Sao Paulo)       Date:  2010-05       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.